Title:
CANCER TREATMENT METHOD
Document Type and Number:
WIPO Patent Application WO2005120512
Kind Code:
A3
Abstract:
The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.
Inventors:
BERGER MARK S (US)
GILMER TONA MORGAN (US)
PANDITE ARUNDATHY NIRMALINI (US)
GILMER TONA MORGAN (US)
PANDITE ARUNDATHY NIRMALINI (US)
Application Number:
PCT/US2005/019568
Publication Date:
April 27, 2006
Filing Date:
June 03, 2005
Export Citation:
Assignee:
SMITHKLINE BEECHAM CORK LTD (IE)
BERGER MARK S (US)
GILMER TONA MORGAN (US)
PANDITE ARUNDATHY NIRMALINI (US)
BERGER MARK S (US)
GILMER TONA MORGAN (US)
PANDITE ARUNDATHY NIRMALINI (US)
International Classes:
A61K31/45; A61K31/337; A61K31/47; A61K31/4745; A61K31/517; A61K31/7068; A61K39/395
Foreign References:
| US20030096789A1 | 2003-05-22 | |||
| US5786344A | 1998-07-28 |
Other References:
ZHOU H ET AL: "Effects of the EGFR/HER2 kinase inhibitor GW572016....", INT J RADIAT ONCOL BIOL PHYS., vol. 58, no. 2, 1 February 2004 (2004-02-01), pages 344 - 352, XP002996475
HERBST R S ET AL: "Monoclonal antibodies to target epidermal growth factor receptor-positive tumors.", CANCER., vol. 94, no. 5, 1 March 2002 (2002-03-01), pages 1593 - 1611, XP002996476
INGLE J N.: "Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.", CLINICAL CANCER RESEARCH., vol. 10, no. 1, 1 January 2004 (2004-01-01), pages 362S - 367S, XP002996477
RUSNAK DW ET AL: "The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.", MOL CANCER THER., vol. 1, December 2001 (2001-12-01), pages 85 - 94, XP002964819
"Cecil Textbook of Medicine.", 2000, GOLDMAN AND BENNET EDITORS., pages: 1068, XP008062637
HERBST R S ET AL: "Monoclonal antibodies to target epidermal growth factor receptor-positive tumors.", CANCER., vol. 94, no. 5, 1 March 2002 (2002-03-01), pages 1593 - 1611, XP002996476
INGLE J N.: "Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.", CLINICAL CANCER RESEARCH., vol. 10, no. 1, 1 January 2004 (2004-01-01), pages 362S - 367S, XP002996477
RUSNAK DW ET AL: "The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.", MOL CANCER THER., vol. 1, December 2001 (2001-12-01), pages 85 - 94, XP002964819
"Cecil Textbook of Medicine.", 2000, GOLDMAN AND BENNET EDITORS., pages: 1068, XP008062637
Download PDF: